Table 1.

Baseline characteristics (safety population).

Characteristic	Group A (midazolam + denosumab*) (N = 19)	Group B (Midazolam Alone†) (N = 8)
Gender, n (%)
Female	19 (100.0)	8 (100.0)
Race, n (%)
White	17 (89.5)	6 (75.0)
Black/African American	1 (5.3)	1 (12.5)
Asian	1 (5.3)	1 (12.5)
Age (years)
Mean (SD)	64.4 (6.16)	66.3 (5.34)
Range	55–73	59–75
≥65 years, n (%)	12 (63.2)	4 (50.0)
Bone mineral density T-score, mean (SD)
Total hip	−2.07 (0.68)	−2.15 (0.65)
Lumbar spine	−2.96 (0.76)	−2.68 (0.92)

SD, standard deviation.

^*Midazolam 2 mg orally on day 1 and day 16, and denosumab 60 mg subcutaneously on day 2.

^†Midazolam 2 mg orally on day 1 and day 16.